The hardest problem in medicine is also the most human.
More than 10,000 rare diseases affect an estimated 300 million people worldwide. Fewer than 5% have an approved therapy. Rare disease pathways demand a different model.
Small, scattered populations. Long diagnostic journeys. Limited natural history. Complex regulatory categories. Rare disease is not a smaller version of common disease — it is a different discipline.
On average, a rare disease patient waits five to seven years and consults multiple specialists before receiving a correct diagnosis. That interval carries clinical, emotional and structural cost.
Advanced pulmonary & interstitial lung disease
Complex pulmonary presentations, ILD and pulmonary hypertension programs.
Genetic & metabolic disorders
Enzyme replacement, gene therapy and small-molecule modalities.
Neuromuscular conditions
Progressive and ultra-rare neuromuscular presentations.
Pediatric rare diseases
Early-onset conditions with limited natural history and long diagnostic journeys.
Rare oncology
Precision programs anchored in molecular characterization.
Other high-need therapeutic areas
Selected programs where scientific innovation meets structural unmet need.
Human expertise. AI-enabled infrastructure.
Rare disease intelligence is not technology alone. It requires clinical judgment, specialist interpretation and local medical credibility, supported by data infrastructure that organizes and prioritizes complex information for physicians, investigators and program teams.
- 01
Identify
Phenotypic signals and investigator networks.
- 02
Coordinate
Sites, referrals, ethics, patient communities.
- 03
Deliver
Regulatory pathways, access, distribution.
- 04
Sustain
Longitudinal data, cohort continuity, real-world evidence.
We work alongside patient organizations, investigators and clinicians. We do not diagnose patients. We do not replace medical judgment. We build the infrastructure that lets both operate at their best.
Building rare disease infrastructure, together.
If you are advancing a therapy, investing in the space, running a clinical program or coordinating patient identification — start a conversation with us.